20. DEUTSCHER ALLERGIE KONGRESS

Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat

Markus Magerl,[1,2] Inmaculada Martinez-Saguer,[3] William R. Lumry,[4] John Anderson,[5] Jonathan A. Bernstein,[6] Mauro Cancian,[7] Danny M. Cohn,[8] Henriette Farkas,[9] H. Henry Li,[10] James Hao,[11] Michael D. Smith,[11] Paolo Bajcic,[11] Paul K. Audhya,[11] Petra Staubach-Renz,[12] Emel Aygören-Pürsün[13]

[1]Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; [2]Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; [3]HZRM Hämophilia Center Rhein Main, Frankfurt, Germany; [4]AARA Research Center, Dallas, TX, USA; [5]Clinical Research Center of Alabama, an affiliate of AllerVie Health, Birmingham, AL, USA; [6]University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, OH, USA; [7]Departmental Allergy Division, Department of Systems Medicine, University of Padua, Padua, Italy; [8]Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands; [9]Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary; [10]Institute for Asthma and Allergy, Wheaton, MD, USA; [11]KalVista Pharmaceuticals, Salisbury, UK, and Framingham, MA, USA; [12]Department of Dermatology, University Medical Center, Mainz, Germany; [13]University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany

Disclosures: Markus Magerl has received grants, honoraria, and/or medical writing support from KalVista Pharmaceuticals, CSL Behring, Takeda, Pharming, BioCryst, Novartis, Octapharma, Intellia Therapeutics, and Pharvaris.

Background

- Treatment guidelines recommend people living with HAE treat attacks with on-demand medication as early as possible to arrest progression of swelling, thereby reducing severity and morbidity, shortening total attack duration, and reducing disruption in daily activities[1,2]
- Sebetralstat, an oral plasma kallikrein inhibitor, has been approved for the treatment of acute HAE attacks in patients ≥12 years old in the US, UK, and the EU[3-5]
- This post hoc analysis examined the time to end of HAE attack progression following sebetralstat treatment in KONFIDENT-S and KONFIDENT
- Time to end of progression was defined as the time at which the worst attack severity was recorded within 4 hours of onset using the PGI-S scale

1. Busse PJ, et al. *J Allergy Clin Immunol Pract*. 2021;9(1):132-150. 2. Maurer M, et al. *Allergy*. 2022;77(7):1061-1990. 3. EKTERLY (sebetralstat). Prescribing information. KalVista Pharmaceuticals, Inc; 2025. 4. EKTERLY (sebetralstat). Summary of product characteristics. UK prescribing information. KalVista Pharmaceuticals, Inc; 2025. 5. EKTERLY (sebetralstat). Summary of Product Characteristics. EU prescribing information. KalVista Pharmaceuticals, Inc; 2025.
HAE, hereditary angioedema. PGI-S, Patient Global Impression of Severity.

HAE Attack Characteristics at Time of Treatment

	KONFIDENT-S[a] Sebetralstat 600 mg n=1591	KONFIDENT[b] Sebetralstat 300 mg n=84	KONFIDENT[b] Sebetralstat 600 mg n=88
Baseline PGI-S rating, n (%)			
Mild[c,d]	594 (37.3)	36 (42.9)	40 (45.5)
Moderate	668 (42.0)	33 (39.3)	30 (34.1)
Severe	262 (16.5)	12 (14.3)	16 (18.2)
Very severe	58 (3.6)	2 (2.4)	2 (2.3)
Time to treatment, median (IQR), min	14.5 (1.0-76.0)	36.0 (7.0-131.0)	38.5 (4.5-141.0)

Data from 134 participants treating 1591 attacks in KONFIDENT-S and 110 participants treating 172 attacks in KONFIDENT were analyzed

[a]KONFIDENT-S: NCT05505916, EudraCT: 2021-001176-42; data cutoff: September 14, 2024. [b]KONFIDENT: NCT05259917; EudraCT: 2021-001226-21; data cutoff: January 31, 2024 [c]PGI-S rating of "None" included in "Mild": KONFIDENT-S sebetralstat 600 mg, 23 (1.4%). [d]PGI-S missing: KONFIDENT sebetralstat 300 mg, 1 (1.2%); KONFIDENT-S sebetralstat 600 mg, 9 (0.6%). IQR, interquartile range; n, number of attacks.

Time to End of Progression

KONFIDENT-S



KONFIDENT



The time to end of HAE attack progression closely followed the expected time to near-complete inhibition of plasma kallikrein (15 minutes) based on prior pharmacodynamic studies[1]

Time to end of progression was defined as the time at which the worst HAE attack severity was recorded using the PGI-S scale within 4 hours. h, hours.

1. Aygören-Pürsün E, et al. *Lancet.* 2023;401(10375):458-469.

Time Course of Sebetralstat-treated Attacks in KONFIDENT-S



Oral sebetralstat allowed for rapid treatment and halted HAE attack progression early

[a]Based on data cutoff date of January 31, 2024. [b]Based on data cutoff date of September 14, 2024. [c]Defined as a PGI-C rating of at least "A Little Better" for at least 2 consecutive time points within 12 hours. [d]Defined as time to substantial reduction of symptom burden (PGI-S of "Mild" for 2 consecutive time points) within 24 hours. Graph generated based on median time to endpoints as observed in the KONFIDENT-S open-label extension study. Area under curve represents the treatment burden. Dashed line is representative of attack onset. PGI-C, Patient Global Impression of Change.